

**March 2010**

Volume 15 · Numbers 5/6

pp. 161–252

**Cover Story**

The featured review by Anupa R. Menjoge, Rangaramanujam M. Kannan and Donald A. Tomalia in this issue of *Drug Discovery Today* deals with the field of dendrimer-based drug delivery. As mentioned in the article, dendrimers have been widely adopted as a result of their unique polymer architecture that makes them ideal as a molecular scaffold capable of conjugating, complexing or encapsulating drugs or imaging moieties. The review specifically concentrates on the role of dendrimers as nano scaffolds and containers; strategies in reducing cytotoxicity; current understanding of dendrimer cellular transport and their use as high contrast MRI imaging agents.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

- 171 Foundation review: Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications**

Anupa R. Menjoge, Rangaramanujam M. Kannan and Donald A. Tomalia

- 186 Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection**

Jian J. Tan, Xiao J. Cong, Li M. Hu, Cun X. Wang, Lee Jia and Xing-Jie Liang

GENE TO SCREEN

- 198 Homologous recombination in human iPS and ES cells for use in gene correction therapy**

Manabu Nakayama

INFORMATICS

- 203 A structural informatics approach to mine kinase knowledge bases**

Natasja Brooijmans, Dominick Mobilio, Gary Walker, Ramaswamy Nilakantan, Rajiah A. Denny, Eric Feyfant, David Diller, Jack Bikker and Christine Humblet

POST SCREEN

- 210 IAP antagonists: promising candidates for cancer therapy**

Raimund Mannhold, Simone Fulda and Emanuele Carosati

- 220 Rationalizing the chemical space of protein–protein interaction inhibitors**

Olivier Sperandio, Christelle H. Reynès, Anne-Claude Camproux and Bruno O. Villoutreix

- 230 Does R&D pay?**

David Cavalla and Raman Minhas

- 235 The future of non-human primate use in mAb development**

Kathryn L. Chapman, Nick Pullen, Laura Andrews and Ian Ragan

- 243 Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy**

Lawrence R. Dick and Paul E. Fleming

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Kirsty Strawbridge**Content Development Manager:** Joanna Aldred**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics
Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in
Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong,
Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis,
USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica,
China***Pradeep Nathan** *Experimental Medicine, GSK and
University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug
Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston,
USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information
Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical
School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

161 Disease models – one size does not fit all*Kaare Kemp*

PERSPECTIVE

FEATURE**163 The strategy of enantiomer patents of drugs***Israel Agranat and Silvya R. Wainschtein*

MONITOR

250 A new approach for treating pancreatic cancer*Michael A. Walker***251 DIARY**